Home › Research › Cognitive tests and assessment
Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial
Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA, Tarenflurbil Phase II Study investigators.. The Lancet. Neurology, 2008-04-29
Topic: Amyloid, tau and blood-test diagnosis
Plain-language summary
Background The amyloid-beta peptide Abeta(42) has been implicated in the pathogenesis of Alzheimer's disease (AD). We aimed to test the effects of tarenflurbil, a selective Abeta(42)-lowering agent (SALA), on cognition and function in patients with mild to moderate AD. Methods 210 patients living in the community who had a mini-mental state examination (MMSE) score of 15-26 were randomly assigned to receive tarenflurbil twice per day (400 mg [n=69] or 800 mg [n=70]) or placebo (n=71) for 12 months in a phase II, multicentre, double-blind study.
What this study adds
Evidence grade: Low
This is a trial of 69 participants. In this 12-month phase II trial, 210 patients with mild to moderate Alzheimer's disease took tarenflurbil, a drug intended to lower amyloid-beta 42, or placebo. Reported effect size: or=0.10; 46.4%; 35.7%.
Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.
Cite this study APA, Vancouver, BibTeX · download .bib or .ris
APA 7th
Wilcock, G. K., Black, S. E., Hendrix, S. B., Zavitz, K. H., Swabb, E. A., Laughlin, M. A., et al. (2008). Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. The Lancet. Neurology. https://doi.org/10.1016/s1474-4422(08)70090-5
Vancouver
Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA, et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. The Lancet. Neurology. 2008. doi:10.1016/s1474-4422(08)70090-5. PMID: 18450517.
BibTeX
@article{wilcock2008-18450517,
author = {Wilcock, G. K. and Black, S. E. and Hendrix, S. B. and Zavitz, K. H. and Swabb, E. A. and Laughlin, M. A. and {Tarenflurbil Phase II Study investigators}},
title = {{Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial}},
journal = {The Lancet. Neurology},
year = {2008},
doi = {10.1016/s1474-4422(08)70090-5},
pmid = {18450517},
url = {https://doi.org/10.1016/s1474-4422(08)70090-5}
}
Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record names 7 authors; APA and Vancouver show the first six, BibTeX and the downloads carry all of them. Check the citation against the original before you use it.
Key findings
- We aimed to test the effects of tarenflurbil, a selective Abeta(42)-lowering agent (SALA), on cognition and function in patients with mild to moderate AD.
- Methods 210 patients living in the community who had a mini-mental state examination (MMSE) score of 15-26 were randomly assigned to receive tarenflurbil twice per day (400 mg [n=69] or 800 mg [n=70]) or placebo (n=71) for 12 months in a phase II, multicentre, double-blind study.
- Primary efficacy outcomes were the AD assessment scale cognitive subscale (ADAS-cog), the Alzheimer's Disease Cooperative Study activities of daily living scale (ADCS-ADL), and the clinical dementia rating sum of boxes (CDR-sb).
- In a 12-month extended treatment phase, patients who had received tarenflurbil continued to receive the same dose, and patients who had received placebo were randomly assigned to tarenflurbil at 800 mg or 400 mg twice per day.
Why it matters
In this 12-month phase II trial, 210 patients with mild to moderate Alzheimer's disease took tarenflurbil, a drug intended to lower amyloid-beta 42, or placebo. The study was designed to test effects on cognition and function; it is an early-phase trial and does not establish that the drug works.
Study details
- Participants69
- Effect sizeor=0.10; 46.4%; 35.7%
- Evidence strengthLow
How this study scored 68/100
Published in a leading specialty journal, and it is a randomized controlled trial.
| Component | Points | Why |
|---|---|---|
| Journal tier | 9 / 10 | Tier 2 — leading specialty journal (The Lancet. Neurology) |
| Journal's citation record | 3 / 4 | The Lancet Neurology: journal h-index 457 (OpenAlex, 2026-10-29) |
| Study design | 11 / 12 | A randomized controlled trial (from PubMed type “Randomized Controlled Trial”) |
| Strength of evidence | 1 / 5 | Rated “low” in our summary |
| Peer-review validation | 10 / 10 | Peer-reviewed. Published as an article in a named peer-reviewed journal. |
| How recent | 1 / 5 | 2008 — within 20 year(s) of the newest study here |
| Sample size | 1 / 4 | 69 participants |
| Effect reported | 2 / 3 | Effect reported as a number, without an interval or test |
| Studied in people | 3 / 3 | Studied in people (participant count stated) |
| Randomized / blinded | 2 / 2 | Randomized and blinded or placebo-controlled (as stated in the record) |
| Times cited | 5 / 7 | Cited 290 times (OpenAlex, 2026-10-10) |
| Citations per year | 3 / 5 | 14.5 citations a year over 20 year(s) since 2008 |
| Impact for its field and year | 5 / 6 | Cited 24.1× the average for papers of its field and year (OpenAlex FWCI) |
| Cited by studies here | 3 / 6 | Cited by 15 other studies in this library |
| Still being cited | 2 / 4 | Cited 29 times in 2024–2026 (2026 still in progress; OpenAlex) |
| Senior author's track record | 1 / 4 | Last-listed author Mark A Laughlin: h-index 19 (OpenAlex, whole career) |
| Institution's track record | 2 / 3 | University of Oxford: institution h-index 2,205 (OpenAlex) |
| Multicenter collaboration | 2 / 3 | OpenAlex lists 5 institution(s) in 3 countries |
| Indexed in PubMed | 2 / 2 | Indexed in PubMed (PMID 18450517) |
| Free to read | 0 / 2 | Behind a paywall — scores zero |
| Total | 68 / 100 | — |
What each of these 20 components measures, and what this score is not →
Read the original
May need a subscription OpenAlex found no free copy of the full text (checked 6 Feb 1020), so the publisher may charge for it. The PubMed abstract is free.
Related
Studies in the library that share something with this one. The line above each title says what.
Studies this one cites
Referenced by this study and also in the alzhub library, so you can read them here.
Later studies that cite this one
15 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.
Related studies in Cognitive tests and assessment from nearby years
Also tagged “trial”
783 studies in the library carry the topic tag “trial”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 783 tagged studies.